Accelerated Approval Should Be Less 'Wide Open,' Califf Says
Executive Summary
FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.
You may also be interested in...
Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
Emails reveal company wanted timelines and approval commitments from FDA toward the end of the eteplirsen review, saying it might not be able to continue studies; at the same time, Sarepta was telling investors it had 12 months of cash on hand.
FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'
Investor compares the development construct to homeopathic medicine.
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
FDA commissioner offers new details about why he left final decision on Sarepta's controversial Duchenne muscular dystrophy drug to FDA's expert bureaucrats.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: